Introduction
The inflammasome complex is formed by NLRP3, along with the adaptor protein pycard (ASC) and pro-caspase-1, which, when activated by various endogenous and microbe-derived danger signals, directs the autocleavage and processing of procaspase-1 (1). Activated caspase-1 cleaves both pro-IL-1β and pro-IL-18 to their mature, secretory forms but has also been shown to result in pyroptosis, a proinflammatory form of programmed cell death (2, 3) . NLRP3 has been implicated in the pathogenesis of numerous human diseases including gout, atherosclerosis, and Alzheimer's disease (4) .
Gain-of-function missense mutations in NLRP3 cause the autoinflammatory disease spectrum known as the cryopyrinassociated periodic syndromes (CAPS), characterized by inflammatory symptoms involving skin, muscles, joints, conjunctiva, and the CNS (5) . CAPS represent a continuum in disease severity, with neonatal-onset multisystem inflammatory disease (NOMID) at the severe end, characterized by continuous inflammatory symptoms with accompanying neurological impairment and deforming arthropathy; the intermediate Muckle-Wells syndrome (MWS), with recurrent inflammatory episodes and a risk of long-term sequelae such as hearing loss and amyloidosis; and familial cold autoinflammatory syndrome (FCAS) at the mild end, with inflammatory symptoms often associated with generalized cold exposure (6) . IL-1 blockade has been largely successful in the treatment of CAPS, however, there are increasing reports of incomplete clinical responses (our unpublished clinical observations), emphasizing the need for further understanding of the disease mechanisms and novel drug development.
Knockin mouse models of Nlrp3 inflammasomopathies have served as important and translatable tools to understand CAPS disease pathogenesis, demonstrating that disease is primarily driven by the innate immune system and specifically by inflammatory cells of myeloid cell lineage (7, 8) . As in human CAPS, IL-1β has been shown to play a major role in CAPS disease pathogenesis in mice, however, additional mechanisms appear to be involved (9) . Clear and independent roles were previously defined for IL-1 and IL-18 signaling in disease progression using KO mice deficient in Il1r or Il18r. However, when both cytokine pathways were disrupted using double-KO mice for Il1r and Il18, a substantial disease phenotype remained, suggesting potential contributions from pyroptosis or other NLRP3 inflammasome-driven mechanisms (9) .
The NLRP3 inflammasome is a protein complex responsible for caspase-1-dependent maturation of the proinflammatory cytokines IL-1β and IL-18. Gain-of-function missense mutations in NLRP3 cause the disease spectrum known as the cryopyrin-associated periodic syndromes (CAPS). In this study, we generated Nlrp3-knockin mice on various KO backgrounds including Il1b/Il18-, caspase-1-, caspase-11-(Casp1/11-), and Tnf-deficient strains. Figure 1A ). Analysis of spleens from these mice revealed marked splenomegaly and a significant neutrophilic infiltrate, as shown by immunohistologic staining for myeloperoxidase (MPO), which was not present in Nlrp3 L351P Casp1/11 -/-or control mice (Figure 1, B-D) . We observed no changes in macrophage numbers or distribution or other pathologic changes in the spleens from these mice. This implicates an NLRP3 inflammasome-and caspase-1-and/or caspase-11-mediated proinflammatory pathology that is independent of both IL-1β and IL-18.
To further examine the mechanisms driving disease in CAPS mice, we attempted to exaggerate the NLRP3 inflammasomemediated inflammatory response by challenging the groups of mice described above in a sublethal endotoxic shock model. We injected LPS i.p. and observed the mice over the next 24 hours for survival and measured serum cytokine levels. Survival analysis of mice injected i.p. with LPS (10 μg/g) showed that 80% of the To further elucidate systemic autoinflammatory disease mechanisms other than IL-1β and IL-18, we generated Nlrp3
L351P

Il1b
-/-Il18 -/-mice. Phenotypic characterization of these mice at 6 months of age or older revealed systemic inflammation dependent on caspase-1 and/or caspase-11 and a marked elevation in serum TNF levels following in vivo LPS challenge. This finding prompted a more in-depth evaluation of TNF in our CAPS mouse models. Treatment of Nlrp3 A350V mice with the TNF inhibitor etanercept or breeding onto a Tnf -/-background provided phenotypic rescue. Our results indicate that TNF plays an unexpected and significant role in murine inflammasomopathies and suggest the existence of another important mediator in the development and progression of these autoinflammatory disorders.
Results
We previously showed that NLRP3 inflammasome-mediated IL-1β, IL-18, and cell death play distinct spatial and temporal roles in the pathogenesis of CAPS (9) . In order to further elucidate non-IL-1β/IL-18-dependent disease mechanisms, we generated Cre lysozyme (LysM-Cre) conditional myeloid-restricted Nlrp3 (8) . Nlrp3 A350V pups were treated with the TNF inhibitor etanercept beginning on day 2 and ending on day 12 of life. Surprisingly, the treatment normalized growth during the treatment period and prolonged survival for an average of 23 days after cessation of treatment ( Figure 3 , A-C). The improved survival and growth parameters suggest that targeting TNF has the potential to significantly reduce NLRP3 inflammasome-mediated inflammation, despite the presence of existing systemic inflammatory symptoms (skin abscesses) at birth.
Following the therapeutic success of etanercept, we decided to further study the role of TNF in murine CAPS using a genetic approach. We crossed Nlrp3 A350V mice with Tnf -/-mice to generate Cre lysozyme-conditional (LysM-Cre-conditional), myeloidrestricted mutant mice on mice, which died after 9 days on average, suggesting a gene dosage-dependent effect of TNF expression on the disease pathology of CAPS mice ( Figure 4A ). Furthermore, Nlrp3
A350V Tnf -/-mice had normal phenotypic appearance and growth, in contrast to the skin erythema, hair growth defect, and poor weight gain observed in Nlrp3 A350V mice on a Tnf-intact background. Nlrp3 A350V Tnf +/-mice showed an intermediate phenotype with respect to skin rash, hair growth, and weight ( Figure 4 , B and C). Analysis of spleen weights from these animals as a percentage of total body weight revealed marked splenomegaly in the Nlrp3 A350V and Nlrp3 A350V Tnf +/-mice, with a significant reduction in the spleen weights of Nlrp3
A350V
Nlrp3
L351P Il1b -/-Il18 -/-mice died within 9 hours of injection and 100% of the control and Nlrp3 L351P Casp1/11 -/-mice survived (Figure 2A) . We then injected a nonlethal dose of LPS (5 μg/g) and performed ELISA to measure serum levels of the proinflammatory cytokines IL-6, IL-1α, IL-17, KC (also called IL-8), and TNF at baseline and 2 and 6 hours after injection. We observed no significant differences in serum IL-6, IL-1α, IL-17, or KC levels between Nlrp3 L351P Il1b -/-Il18 -/-and Nlrp3 L351P Casp1/11 -/-mice at either time point (Supplemental Figure 1 ; supplemental material available online with this article; https://doi.org/10.1172/JCI90699DS1). Baseline values for TNF were undetectable in all groups (data not shown), however a marked elevation of serum TNF levels was noted 2 and 6 hours after LPS injection in Nlrp3 L351P Il1b -/-Il18 -/-mice but was not observed in the control or Nlrp3 L351P Casp1/11 -/-animals ( Figure 2B ). These results suggest that LPS drives TNF in serum in these mice in a NLRP3 inflammasome-and caspase-1-and/or caspase-11-dependent, but IL-1β-and IL-18-independent, manner.
We next investigated whether our findings in CAPS mice are translatable to human CAPS patients. Baseline and post-treatment measurements of serum cytokine levels were collected from a longitudinal study of NOMID patients on anakinra (IL-1 receptor antagonist) (10) . IL-1 blockade was successful in reducing CAPS-associated symptoms and chronic inflammation in this group of patients, with all treated patients showing a significant reduction in C-reactive protein (CRP) ( Figure 2C ). Interestingly, Tnf -/-mice, indicating a reduction in inflammatory (type 1) macrophages in the spleens from these animals ( Figure 6B ). Consistent with our histologic observations, the expression of neutrophilic markers, including Mpo, Cxcl1, and Cxcl2, was also significantly reduced in Nlrp3 A350V Tnf -/-mice ( Figure 6 , B and C). We also measured splenic mRNA expression of inflammasome components and found significant reductions in the expression of Nlrp3, Asc, and pro-Casp1 in Nlrp3 A350V Tnf -/-mice, with similar decreases seen in expression of the pro-cytokines IL-1β and IL-18 in spleens from these mice compared with those from Nlrp3 A350V animals. Intermediate mRNA expression levels were detected in Nlrp3 To further explore the regulatory role of TNF on inflammasome-mediated disease and rule out the possibility that the observed difference in expression levels of inflammasome components and pro-cytokines in spleens from mutant mice on a TNF-deficient background was not due simply to differences in the number of infiltrating myeloid cells, we cultured BM-derived DCs (BMDCs) from previously described inducible Nlrp3
A350V
Cre-ERT2 mice (8) and similarly age-matched adult Nlrp3
Tnf
-/-mice. We found that the expression levels of pro-Casp1 and pro-Il1b mRNA were significantly reduced in Nlrp3 A350V Tnf -/-cells as compared with levels in Nlrp3 A350V Cre-ERT2 cells ( Figure 7A ). Stimulation of BMDCs with 1 ng/ml LPS elevated the mRNA levels of all genes studied and essentially equalized the expression values in the 2 groups, with no differences seen in any of the measured inflammasome components or pro-cytokines ( Figure 7B ). To determine whether TNF has an effect on inflammasome oligomerization, we used immunofluorescence to visualize and quantify ASC specks from Nlrp3 A350V Cre-ERT2 and Nlrp3 A350V Tnf -/-BMDCs and observed no significant differences before or after stimulation with LPS (Supplemental Figures 3 and 4) . Similarly, we observed no significant differences in secreted mature IL-1β levels in cell supernatants (Supplemental Figure 3) . Together, these data suggest that TNF is an important regulator at the transcriptional level for the NLRP3 inflammasome in murine CAPS.
-/-animals ( Figure 4D ). Measurement of serum cytokine levels revealed significant decreases in both IL-1β and IL-18 in Nlrp3 Skin histology of Nlrp3 A350V pups showed a marked inflammatory cell infiltrate in the dermis that primarily consisted of neutrophils and a lack of s.c. fat ( Figure 5A ). Figure 5A ). Moreover, we found that dermal thickness was increased in the Nlrp3 A350V mice and markedly reduced in the Nlrp3 A350V Tnf -/-animals (
Figure 5B Figure 2) . We also noted elevated Cxcl1 and Cxcl2 expression levels in Nlrp3 A350V skin that were markedly reduced in Nlrp3 A350V Tnf -/-skin and slightly reduced in Nlrp3 A350V Tnf +/-skin (Supplemental Figure 2) . These results are consistent with macrophage-and possibly mast cellmediated chemokine release, resulting in a neutrophilic infiltrate that is also TNF mediated (11 Our discovery that serum levels of TNF were elevated in LPS-treated mutant mice in an inflammasome-dependent fashion, independent of IL-1β and IL-18, may be due to noncanonical inflammasome activation through caspase-11. This was described previously in LPS-induced sepsis models, but the responsible downstream cytokine was not identified (16) . It is also possible that the elevated TNF levels in patients with NOMID and in the serum of mutant mice could be due to direct activation of NF-κB by the mutant NLRP3 inflammasome, a mechanism that has been demonstrated previously in some in vitro systems (17) but has not been shown conclusively in vivo. While inhibition of TNF in our KO models or via etanercept treatment demonstrates an important role for TNF in CAPS, it is not clear whether TNF is the primary driver of the remaining phenotype observed in our mice and in NOMID patients with an incomplete response to IL-1 blockade, or merely a key checkpoint in a complex inflammatory cascade.
TNF is a proinflammatory cytokine that is predominantly produced by activated macrophages to regulate the immune response. It acts as an endogenous pyrogen capable of inducing inflammation, apoptotic cell death, and cachexia. Consequently, dysregulation of TNF has been implicated in many inflammatory human diseases including psoriasis and inflammatory bowel
Discussion
Recent studies of CAPS in humans and mice have advanced our knowledge of the NLRP3 inflammasome (12, 13) and the roles of both IL-1β and IL-18 in the subsequent inflammatory cascade (9) . While translational studies have resulted in pivotal therapies for patients with CAPS (14, 15), many patients continue to have incomplete clinical responses, suggesting that our understanding of the inflammasome and other caspase-1-dependent pathways is incomplete. In this study, we took advantage of mutant Nlrp3-knockin mouse lines deficient in both IL-1β and IL-18 to investigate these alternate pathways.
Our studies demonstrated a clear caspase-1-and/or caspase-11-dependent inflammatory phenotype that was present in the Nlrp3 L351P Il1b -/-1l18 -/-mice as they aged. Although IL-1β and IL-18 both play prominent and distinct roles in murine disease pathology, residual inflammation remains, indicating that other mechanisms or inflammatory mediators are present. Here, we were able to show a significant role for TNF in the development and progression of murine inflammasomopathies through both genetic KO and targeted therapeutic treatment with etanercept, with either approach rescuing the early disease phenotype. We were further able to show a regulatory role for TNF at the level of pro-cytokine and inflammasome component mRNA expression. disease (18, 19) . TNF and IL-1β have been shown to strongly synergize in numerous biological functions, both in vitro and in vivo (20) . Furthermore, TNF has been shown to induce IL-1β in human monocytes. TNF also enhances ATP-or silica-mediated caspase-1 and IL-1β secretion in murine macrophages and dendritic cells (21, 22) . Although the effects of TNF and IL-1β overlap, they can have somewhat differing roles in the inflammatory cascade. In this study, we show significant decreases in both serum IL-1β and IL-18 levels as the result of TNF ablation, implicating the importance of TNF in inflammation and, in particular, the early autoinflammatory milieu in murine CAPS. We were surprised to find a gene dosage-dependent effect in skin rash, inflammatory infiltrate, and survival kinetics in the Nlrp3 A350V Tnf +/-mice, in which an intermediate phenotype was observed between Nlrp3 A350V and Nlrp3 A350V Tnf -/-animals. We did not observe this phenomenon in our previously generated mutant mice that were deficient for inflammasome components and cytokines (8, 9, 23) . This may be consistent with the regulatory role of TNF at the transcriptional level, which may allow for better fine-tuning of the inflammatory response.
The interplay between each of these proinflammatory cytokine pathways and the multistep regulation of inflammasome activity is likely to be complex and multifactorial. Our in vivo and in vitro data show significant reductions in splenic pro-cytokine mRNA levels alongside reductions in the upstream mRNA expression of the inflammasome components in Nlrp3 A350V Tnf -/-mice. This finding highlights the regulatory role of TNF in driving transcription of the cytokines and inflammasome components and may explain how targeting TNF in CAPS mice provides such a pronounced phenotypic rescue. Translating these findings, treatment of Nlrp3 A350V pups with the TNF inhibitor etanercept was highly effective in normalizing both growth kinetics and systemic disease, even after the onset of inflammatory symptoms, as pups were born with skin abscesses that quickly cleared after beginning treatment on day 2 of life. A similar observation was made with an anti-TNF-α-blocking IgG antibody treatment that predominantly affected the skin of a less severe knockin mutant mouse (Nlrp3
R258W
) (24, 25) . Given that some CAPS patients experience an incomplete clinical response to IL-1-targeted therapy and that some patients on therapy in our study had elevated serum TNF levels, the question remains whether select patients would benefit from TNF blockade in com- , and Il1b -/-Il18 -/-mice older than 6 months were given a single i.p. injection of LPS from E. coli 0127:B8 (Sigma-Aldrich). LPS was injected at a concentration of (5 μg/g), and blood was collected by submandibular puncture for serum cytokine analysis 1 day prior to and 2 and 6 hours after injection. For survival studies, LPS was injected at a concentration of 10 μg/g, with survival analysis conducted every 3 hours, up to 24 hours after injection.
NOMID patients. As part of a longitudinal study of pediatric NOMID patients, blood was collected and serum analyzed from patients at baseline and during follow-up appointments at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Autoinflammatory Disease clinic (Bethesda, Maryland, USA), after beginning treatment on anakinra (Swedish Orphan Biovitrum AB [Sobi]), with doses ranging from 2.5 to 5.4 mg/kg/dl. Controls refer to pediatric patients who did not have an autoinflammatory condition. Patients' characteristics and clinical symptoms can be found in Supplemental Table 2 .
Blood, spleen, and skin sample preparation. At the selected time interval, adult mice were anesthetized (ketamine 60 mg/kg plus xylazine 10 mg/kg, i.p.), the peritoneal and thoracic cavities opened, and blood samples obtained via cardiac puncture. Neonates were sacrificed at 6 to 9 days of age and peripheral blood obtained by decapitation. The spleen and skin were harvested and the tissue was divided. A representative tissue section was fixed in 10% formalin for 24 hours and embedded in paraffin, and 50-μg tissue samples were placed into 500 μl of RNAlater Solution (Life Technologies, Thermo Fisher Scientific).
Histology and IHC. For histological evaluation, splenic and skin tissues were stained with H&E. The following primary monoclonal antibodies were used to perform immunostaining: anti-F4/80 (AbDSerotec/Bio-Rad; MCA497) and anti-MPO (Thermo Fisher Scientific; bination with IL-1 inhibition. Prior to the use of IL-1 blockers in CAPS, there were unpublished reports of worsening symptoms in some CAPS patients treated with TNF blockers alone. Therefore, further studies are required to better understand the complex role that TNF plays in human CAPS pathology. Patients on combination therapy would also need to be monitored closely, as an increased infection rate was observed in rheumatoid arthritis patients treated with anakinra and etanercept together, without additional therapeutic benefit (26) . However, the prominent regulatory role for TNF in inflammasome function and the significant reduction in murine CAPS pathology with TNF blockade make this a potential adjunctive therapeutic option in the future.
Methods
Mouse strains. Nlrp3
L351PneoR and Nlrp3 A350VneoR mice were generated as previously described, with leucine 351 to proline (L351P) and alanine 350 to valine (A350V) substitutions, respectively. 
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